{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:38:15Z","timestamp":1787931495713,"version":"build-2784847793"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal timing of vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines after cellular therapy is incompletely understood. The objectives of this study are to determine whether humoral and cellular responses after SARS-CoV-2 vaccination differ if initiated &amp;lt;4 months versus 4\u201312 months after cellular therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, prospective, observational study at 30 cancer centers in the United States. SARS-CoV-2 vaccination was administered as part of routine care. We obtained blood prior to and after vaccinations at up to 5 time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2\u2013specific T-cell receptors, in a subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 466 allogeneic hematopoietic cell transplantation (HCT) (n = 231), autologous HCT (n = 170), and chimeric antigen receptor T-cell (CAR-T-cell) therapy (n = 65) recipients between April 2021 and June 2022. Humoral and cellular responses did not significantly differ among participants initiating vaccinations &amp;lt;4 months versus 4\u201312 months after cellular therapy. Anti-S IgG \u22652500\u2005U\/mL was correlated with high neutralizing antibody titers and attained by the last time point in 70%, 69%, and 34% of allogeneic HCT, autologous HCT, and CAR-T-cell recipients, respectively. SARS-CoV-2\u2013specific T-cell responses were attained in 57%, 83%, and 58%, respectively. Pre\u2013cellular therapy SARS-CoV-2 infection or vaccination and baseline B-cell count were key predictors of post\u2013cellular therapy immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data support mRNA SARS-CoV-2 vaccination prior to, and reinitiation 3 to 4 months after, cellular therapies with allogeneic HCT, autologous HCT, and CAR-T-cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae291","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T16:51:23Z","timestamp":1716569483000},"page":"542-554","source":"Crossref","is-referenced-by-count":28,"title":["SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A","family":"Hill","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease, Fred Hutchinson Cancer Center, and Department of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Martens","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]},{"name":"Division of Biostatistics, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne H","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Bhavsar","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqun","family":"Kou","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lik Wee","family":"Lee","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies Corporation , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah","family":"Baluch","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, H. Lee Moffitt Cancer Center and Research Institute , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, School of Medicine, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology & Hematopoietic Cell Transplantation, City of Hope , Duarte, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Peyton","sequence":"additional","affiliation":[{"name":"The Emmes Company , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna S","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Wake Forest Baptist , Winston-Salem, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uroosa","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mount Sinai Hospital , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Shahid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Armistead","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina Medical Center , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Westervelt","sequence":"additional","affiliation":[{"name":"Division of Oncology, Barnes-Jewish Hospital, Washington University , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McCarty","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology & Palliative Care, Virginia Commonwealth University , Richmond, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas , Lawrence, Kansas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"DeWolf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Hosszu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"National Cancer Institute , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Spahn","sequence":"additional","affiliation":[{"name":"National Marrow Donor Program\/Center for International Blood and Marrow Transplant Research , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A","family":"Toor","sequence":"additional","affiliation":[{"name":"Lehigh Valley Health Network , Allentown, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Waldvogel","sequence":"additional","affiliation":[{"name":"National Marrow Donor Program\/Center for International Blood and Marrow Transplant Research , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M","family":"Greenberger","sequence":"additional","affiliation":[{"name":"The Leukemia and Lymphoma Society, Rye Brook , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery J","family":"Auletta","sequence":"additional","affiliation":[{"name":"National Marrow Donor Program\/Center for International Blood and Marrow Transplant Research , Minneapolis, Minnesota ,","place":["USA"]},{"name":"Division of Hematology\/Oncology\/BMT and Infectious Diseases, Nationwide Children's Hospital , Columbus, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcie L","family":"Riches","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin , Milwaukee, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]},{"name":"Department of Medicine, Weill Cornell Medical College , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"2025052620014546200_ciae291-B1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"2025052620014546200_ciae291-B2","doi-asserted-by":"crossref","first-page":"796.e1","DOI":"10.1016\/j.jtct.2021.07.005","article-title":"Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients","volume":"27","author":"Mushtaq","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B3","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025052620014546200_ciae291-B4","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.jtct.2023.09.027","article-title":"Outcomes and management of the SARS-CoV2 Omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T cell therapy","volume":"30","author":"Infante","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2643-3230.BCD-22-0077","article-title":"Anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with hematologic malignancies","volume":"3","author":"Greenberger","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2025052620014546200_ciae291-B6","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"2025052620014546200_ciae291-B7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination amongst patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"2025052620014546200_ciae291-B8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","article-title":"Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19","volume":"8","author":"Haggenburg","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025052620014546200_ciae291-B9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2021.280494","article-title":"Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation","volume":"107","author":"Einarsdottir","year":"2022","journal-title":"Haematologica"},{"key":"2025052620014546200_ciae291-B10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"},{"key":"2025052620014546200_ciae291-B11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"Redjoul","year":"2021","journal-title":"Lancet"},{"key":"2025052620014546200_ciae291-B12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy\u2014a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B13","doi-asserted-by":"crossref","first-page":"214.e1","DOI":"10.1016\/j.jtct.2022.01.019","article-title":"Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation","volume":"28","author":"Huang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B14","doi-asserted-by":"crossref","first-page":"706.e1","DOI":"10.1016\/j.jtct.2022.07.024","article-title":"Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients","volume":"28","author":"Kimura","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.26769","article-title":"Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: a Japanese multicenter observational study","volume":"98","author":"Mori","year":"2023","journal-title":"Am J Hematol"},{"key":"2025052620014546200_ciae291-B16","doi-asserted-by":"crossref","first-page":"e1169666","DOI":"10.3389\/fimmu.2023.1169666","article-title":"Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study","volume":"14","author":"Barkhordar","year":"2023","journal-title":"Front Immunol"},{"key":"2025052620014546200_ciae291-B17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41409-023-01946-0","article-title":"SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination","volume":"58","author":"Pi\u00f1ana","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2025052620014546200_ciae291-B18","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.jtct.2023.03.005","article-title":"Severe acute respiratory syndrome coronavirus 2 vaccine immunogenicity among chimeric antigen receptor T cell therapy recipients","volume":"29","author":"Aleissa","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtct.2023.12.011","article-title":"Efficacy of multiple SARS-CoV-2 vaccine doses in patients with B cell hematologic malignancies receiving chimeric antigen receptor T cell therapy: a contemporary cohort analysis","volume":"30","author":"Abid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtct.2022.10.010","article-title":"Frequently asked questions on coronavirus disease 2019 vaccination for hematopoietic cell transplantation and chimeric antigen receptor T-cell recipients from the American Society for Transplantation and Cellular Therapy and the American Society of Hematology","volume":"29","author":"Khawaja","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B21","author":"National Comprehensive Cancer Network"},{"key":"2025052620014546200_ciae291-B22","first-page":"30600","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"S1473-3099","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025052620014546200_ciae291-B23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025052620014546200_ciae291-B24","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/cid\/ciad349","article-title":"A phase 3, randomized, double-blind, comparator-controlled study to evaluate safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in allogeneic hematopoietic cell transplant recipients (PNEU-STEM)","volume":"77","author":"Wilck","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025052620014546200_ciae291-B25","doi-asserted-by":"crossref","first-page":"e14109","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25 Suppl 1","author":"Reynolds","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2025052620014546200_ciae291-B26","doi-asserted-by":"crossref","first-page":"706.e1","DOI":"10.1016\/j.jtct.2023.08.008","article-title":"Immunogenicity and safety of booster SARS-CoV-2 mRNA vaccine dose in allogeneic hematopoietic stem cell transplantation recipients","volume":"29","author":"Mittal","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025052620014546200_ciae291-B27","doi-asserted-by":"crossref","first-page":"101983","DOI":"10.1016\/j.eclinm.2023.101983","article-title":"SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study","volume":"59","author":"Hill","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025052620014546200_ciae291-B28","doi-asserted-by":"crossref","first-page":"23921","DOI":"10.1038\/s41598-021-03154-6","article-title":"Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"2025052620014546200_ciae291-B29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"2025052620014546200_ciae291-B30","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/ncomms3680","article-title":"Using synthetic templates to design an unbiased multiplex PCR assay","volume":"4","author":"Carlson","year":"2013","journal-title":"Nat Commun"},{"key":"2025052620014546200_ciae291-B31","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T-cell receptor \u03b2-chain diversity in \u03b1\u03b2 T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"key":"2025052620014546200_ciae291-B32","doi-asserted-by":"crossref","first-page":"eadh4529","DOI":"10.1126\/scitranslmed.adh4529","article-title":"T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19","volume":"15","author":"Zonozi","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025052620014546200_ciae291-B33","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"2025052620014546200_ciae291-B34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/2643-3230.BCD-21-0142","article-title":"Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy","volume":"2","author":"Tamari","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2025052620014546200_ciae291-B35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtct.2022.10.010","article-title":"Frequently asked questions on coronavirus disease 2019 vaccination for hematopoietic cell transplant and chimeric antigen receptor T-cell recipients from the American society for transplantation and cellular therapy and the American society of hematology","volume":"29","author":"Khawaja","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae291\/58373183\/ciae291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/2\/542\/58831822\/ciae291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/2\/542\/58831822\/ciae291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T20:02:01Z","timestamp":1748289721000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/2\/542\/7683259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,27]]},"published-print":{"date-parts":[[2024,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae291","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,15]]},"published":{"date-parts":[[2024,5,27]]}}}